David A. Siegel I Mab Transaction History
Two Sigma Advisers, LP
- $42.5 Billion
- Q1 2024
A detailed history of David A. Siegel (Two Sigma Advisers, LP) transactions in I Mab stock. As of the latest transaction made, Two Sigma Advisers, LP holds 617,100 shares of IMAB stock, worth $975,018. This represents 0.0% of its overall portfolio holdings.
Number of Shares
617,100
Previous 558,700
10.45%
Holding current value
$975,018
Previous $1.06 Million
8.11%
% of portfolio
0.0%
Previous 0.0%
Shares
9 transactions
Others Institutions Holding IMAB
# of Institutions
45Shares Held
16MCall Options Held
11.9KPut Options Held
3.5K-
Hhlr Advisors, Ltd. Grand Cayman, E96.91MShares$10.9 Million0.29% of portfolio
-
Decheng Capital Management Iii (Cayman), LLC4.17MShares$6.58 Million3.04% of portfolio
-
Two Sigma Investments, LP New York, NY576KShares$909,4160.0% of portfolio
-
Temasek Holdings (Private) LTD Singapore, U0567KShares$895,3070.01% of portfolio
-
Gsa Capital Partners LLP London, X0433KShares$683,5410.07% of portfolio
About I-Mab
- Ticker IMAB
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 83,098,800
- Market Cap $131M
- Description
- I-Mab, a clinical stage biopharmaceutical company, discovers, develops, and commercializes biologics to treat cancer and autoimmune disorders. It is developing Felzartamab, a CD38 antibody that is in Phase 1b/2a for patients with membranous nephropathy; Eftansomatropin alfa, a long-acting human growth hormone, which has completed Phase 3 clinica...